DGAP-News

Immunic AG: Immunic successfully closes 17.5 million Euro Series A financing round (news with additional features) - Seite 2

team will substantially advance the therapeutic options in this field."

"I am pleased to see the financing round being completed with the support
of the Bavarian Growth Fund. Just as with other start-ups, our focus with
Immunic is on creating the best possible environment for the development
and implementation of innovative ideas. This is the fundamental idea behind
the Growth Fund. Innovation is the seed of products and enterprises,
creating the jobs of tomorrow. This benefits businesses and people in the
entire region," commented Ilse Aigner, the Bavarian Minister of Economic
Affairs. "I very much look forward to seeing Immunic's clinical development
programs advance and wish its team great success."

- Press release ends -

Further information

About Immunic

Immunic AG is a start-up biotech company founded in April 2016 and focused
on the development of orally available, small molecule immune modulators to
block immune and autoimmune responses. Immunic develops drug candidates
until clinical proof of concept. Immunic, with headquarters in Planegg-
Martinsried near Munich, Germany, is privately held and supported by
several renowned sector investors.

www.immunic.de

Dr. Manfred Gröppel, [e-mail], [phone]

About Life Sciences Partners (LSP)

LSP is a leading independent European investment firm, providing financing
for private and public life-science companies. Since the late 1980s, LSP's
management has invested in a large number of highly innovative enterprises,
many of which have grown to become leaders of the global life-science
industry. With over EUR 1 billion of investment capital raised to date and
offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and
most experienced specialist life-science investors.

www.lspvc.com

About LifeCare Partners (LCP)

LifeCare Partners is an independent investment firm providing financing to
private and public life science companies. LifeCare Partners targets the
entire life science industry with special focus on medical technology,
diagnostics, biopharmaceuticals, food & nutrition, industrial
biotechnology, biomaterials, e-health and bioenergy. Based in Basel, the
LifeCare Partners team has successfully invested in more than 35 life
science companies over the last years, of which a large number have already
been listed on the stock exchange or have been acquired by leading players
in the life science industry.

www.lifecarevc.com

About Bayern Kapital

Bayern Kapital is based in Landshut and was founded on the initiative of
the Bavarian government in 1995. It is a wholly-owned subsidiary of the